A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease
Conclusions
These data suggest that a single dose of MK-0657 7 mg is not effective in improving levodopa-induced dyskinesias and motor symptoms in PD patients.
Clinical trial registration: clinicaltrials.gov NCT00505843 (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Original Articles Source Type: research
Real-World Safety and Patient Profile of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina
Conclusions
The safety and patient profile of fingolimod in a new real-world setting were consistent with information provided from phase III clinical trials. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Original Articles Source Type: research
Successful Use of Escitalopram for the Treatment of Visual Hallucinations in Patients With Parkinson Disease
Conclusions
Escitalopram was well tolerated as treatment of VH in PD patients. This medication could be a promising optional therapy for this disturbance; however, further randomized controlled and bigger studies are necessary. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Original Articles Source Type: research
Early Onset Schizophrenia Associated With Obsessive-Compulsive Disorder: Clinical Features and Correlates
Conclusions
Adolescents with schizophrenia and OCD needed more antipsychotic doses for acute exacerbation and the maintenance of reduction of psychosis severity than adolescents with only schizophrenia. We could suggest that OCD comorbidity in schizophrenia is more treatment resistant, although the severity of the schizophrenia was similar between study groups. There was no correlation between OCD and schizophrenia symptoms either. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Original Articles Source Type: research
Switch From Originator to Equivalent Drug in the Era of Generic Antiepileptic Drugs: Study of Keppra Versus Epitiram Clinical Equivalence
Conclusions
The switch from Keppra to epitiram was easy and safe in our population, and epitiram can be considered as effective and tolerable as Keppra. Only a slight, non–statistically significant variability in LEV serum concentration was documented after the switch from Keppra to epitiram. Larger epileptic populations should be studied to confirm these results. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Original Articles Source Type: research
Inhaled Loxapine for Agitation in Intoxicated Patients: A Case Series
Conclusions: The acute agitation was effectively and quickly managed with inhaled loxapine in all intoxicated patients and enabled the appropriate clinical evaluation of the agitated state and the patient's management. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Case Reports Source Type: research
Subdural Instillation of a Thrombolytic Agent for Treatment of Recurrent Subdural Hematoma
This study aims to report the case of a patient with recurrent subdural hemorrhage (SDH) who was administered tissue plasminogen activator through a subdural drain to enhance drainage and prevent recurrence.
Methods: An 85-year-old man was treated for subacute over chronic SDH that kept on reaccumulating despite serial twist drill drainage, burr hole drainage, and craniotomy. No coagulopathy was identified with adequate blood pressure control.
Results: Treatment with tissue plasminogen activator resulted in successful drainage of the SDH, and the patient had no further recurrence at 9-month follow-up. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Case Reports Source Type: research
Aripiprazole for Post-traumatic Stress Disorder: A Systematic Review
Conclusions: Based on the reviewed literature, aripiprazole is a reasonable therapy option as monotherapy or adjunct therapy in patients with PTSD. Larger randomized controlled trials are needed to better understand the role of this atypical antipsychotic in patients with PTSD. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Review Article Source Type: research
Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience
Conclusions: Medical cannabis was found to improve symptoms of PD in the initial stages of treatment and did not cause major adverse effects in this pilot, 2-center, retrospective survey. The extent of use and the reported effects lend support to further development of safer and more effective drugs derived from Cannabis sativa. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Original Articles Source Type: research
Pramipexole and Electroconvulsive Therapy in Treatment-Resistant Depression
Conclusions: Pramipexole is a therapeutic option for MDD resistant to ECT. It could be used jointly to ECT or after a partial remission with ECT. More studies are needed to precisely describe the optimal combination of sequential use of ECT and pramipexole in treatment-resistant MDD. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Original Articles Source Type: research
The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease
Objectives: The adenosine A2A antagonist istradefylline has been used to treat Parkinson disease (PD) with symptoms of wearing-off since 2013 in Japan. Previous randomized controlled trials of istradefylline compared with placebo included PD patients experiencing an average daily OFF time of more than 2 hours. The purpose of this study is to assess the efficacy of 20 mg/d istradefylline in PD subjects experiencing an average daily OFF time of 3 hours or less.
Methods: Fifteen patients were enrolled into this retrospective study. They received 20 mg/d istradefylline for 12 weeks. Changes in the Unified Parkinson's Disease ...
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Original Articles Source Type: research
A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease
Conclusions: These data suggest that a single dose of MK-0657 7 mg is not effective in improving levodopa-induced dyskinesias and motor symptoms in PD patients.
Clinical trial registration: clinicaltrials.gov NCT00505843 (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Original Articles Source Type: research
Real-World Safety and Patient Profile of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina
Conclusions: The safety and patient profile of fingolimod in a new real-world setting were consistent with information provided from phase III clinical trials. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Original Articles Source Type: research
Successful Use of Escitalopram for the Treatment of Visual Hallucinations in Patients With Parkinson Disease
Conclusions: Escitalopram was well tolerated as treatment of VH in PD patients. This medication could be a promising optional therapy for this disturbance; however, further randomized controlled and bigger studies are necessary. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Original Articles Source Type: research
Early Onset Schizophrenia Associated With Obsessive-Compulsive Disorder: Clinical Features and Correlates
Conclusions: Adolescents with schizophrenia and OCD needed more antipsychotic doses for acute exacerbation and the maintenance of reduction of psychosis severity than adolescents with only schizophrenia. We could suggest that OCD comorbidity in schizophrenia is more treatment resistant, although the severity of the schizophrenia was similar between study groups. There was no correlation between OCD and schizophrenia symptoms either. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2017 Category: Neurology Tags: Original Articles Source Type: research
